Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB25FY22W
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $2,321
Award facts
- Contract value 100% obligated
- $2,321.10 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $2,321.10 by the Defense Logistics Agency (DLA) on August 27, 2025, for the supply of Xolair 150 mg/ml syringes. The contract, awarded without set-aside designation, carries a firm fixed-price structure with an ultimate completion date of September 18, 2025. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a $499.9 billion contract vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products for military health facilities worldwide.
DMS Pharmaceutical Group maintains a robust portfolio of federal pharmaceutical supply contracts with the DLA, specializing in delivering branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare sites. The company's established presence in federal procurement since 2001 and woman-owned small business status have enabled it to compete effectively for direct distribution of medications and pharmacy services supporting military healthcare operations. This delivery order for Xolair, a biologic medication used in the treatment of allergic asthma and chronic spontaneous urticaria, reflects the company's continued role as a critical supplier within the federal pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DB25FY22W?
SPE2DB25FY22W was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 27, 2025.
How much is contract SPE2DB25FY22W worth?
The government has obligated $2,321 on SPE2DB25FY22W.
Is contract SPE2DB25FY22W an order under another contract?
Yes. SPE2DB25FY22W is a delivery order under SPE2DB22D9362, an indefinite delivery contract.
Was contract SPE2DB25FY22W competed?
The extent of competition for SPE2DB25FY22W was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award